NEW YORK (GenomeWeb) – Personalis announced today that it has been awarded a contract to provide clinical cancer genomic testing and analysis services to the US Department of Veterans Affairs for its Precision Oncology Program (POP).
The POP was established to provide advanced clinical care to veterans and create opportunities to discover and validate novel cancer biomarkers. Under the terms of the contract, Personalis will provide its ACE CancerPlus test — which uses next-generation sequencing to generate reports on 181 clinically relevant genes, providing tumor genomic profile data that can help guide therapy and research — to patients in the VA healthcare system.
Additional terms were not disclosed.
"We are extremely pleased to continue our relationship with the VA and support the VA's leadership using genomics to improve veterans' medical care," Personalis President and CEO John West said in a statement. "Through this VA partnership, Personalis has further optimized its platform for difficult-to-sequence FFPE samples, which has resulted in improved sequencing performance for VA customers."
Personalis said that the latest VA contract is its sixth with the agency. The company signed a deal to sequence more than 34,000 additional whole human genomes for the VA's Million Veteran Program earlier this month.